



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
08/958,570	10/28/1997	RICHARD J. GREGORY	16930-000921	3556	
7590 08/27/2004			EXAMINER		
TOWNSEND AND TOWNSEND AND CREW			· GUZO, DAVID		
TWO EMBARCADERO CENTER 8TH FLOOR SAN FRANCISCO, CA 941113834			ART UNIT	PAPER NUMBER	
			1636		
			T-1 T-1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		08/958,570	GREGORY ET AL.			
Office Action Summa	ry	Examiner	Art Unit			
·		David Guzo	1636			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PER THE MAILING DATE OF THIS COM - Extensions of time may be available under the pr after SIX (6) MONTHS from the mailing date of the period for reply specified above is less than - If NO period for reply is specified above, the max - Failure to reply within the set or extended period Any reply received by the Office later than three earned patent term adjustment. See 37 CFR 1.7	IMUNICATION. ovisions of 37 CFR 1.136(nis communication. thirty (30) days, a reply w imum statutory period will for reply will, by statute, comonths after the mailing de	(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days apply and will expire SIX (6) MONTHS from the application to become ABANDONET	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status						
1) Responsive to communication	(s) filed on <u>26 Jul</u> y	<u>/ 2004</u> .				
2a) ☐ This action is FINAL .	2b)⊡ This a	oction is non-final.				
·— ···	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
	practice under Ex	parte Quayle, 1955 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims						
4) Claim(s) 42-74 is/are pending in the application.						
4a) Of the above claim(s)	_ is/are withdrawr	i from consideration.				
5)⊠ Claim(s) <u>42-74</u> is/are allowed. 6)□ Claim(s) is/are rejected.						
7) Claim(s) is/are objected						
8) Claim(s) are subject to		election requirement.				
Application Papers						
9)☐ The specification is objected to	by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	=	n is required if the drawing(s) is objective and National Conference	` '			
11)☐ The oath or declaration is object	ited to by the Exar	miner. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119						
	e of: riority documents I riority documents I	have been received. have been received in Applicatio	on No			
•	•	y documents have been received	d in this National Stage			
application from the Inte * See the attached detailed Office	•	· · · · ·	4			
See the attached detailed Office	action for a list of	the certified copies not received				
Attachment(s)						
1) Notice of References Cited (PTO-892)		4) Interview Summary (
 2) Notice of Draftsperson's Patent Drawing Re 3) Information Disclosure Statement(s) (PTO-1 		Paper No(s)/Mail Dai 5) Notice of Informal Pa	atent Application (PTO-152)			
Paper No(s)/Mail Date	ŕ	6) Other: Notice thin	mps with Sequero Mulis.			

Application/Control Number: 08/958,570

Art Unit: 1636

Detailed Action

This application is in condition for allowance except for the following formal matters:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, the sequence originally present on p. 20 of the specification is identified as SEQ ID NO:9; however, during prosecution, said sequence was amended by applicants to delete a portion of said sequence. A new Sequence Listing reflecting the change in the sequence has not been filed and hence the amended sequence no longer matches SEQ ID NO:9 as present in the as filed Sequence Listing. A new Sequence Listing is therefore required.

A second matter involves the Abstract. The Abstract of record in the application contains two paragraphs. The Abstract should be one paragraph. Correction is required.

Applicant must comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Art Unit: 1636

Prosecution on the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.

A shortened statutory period for reply to this action is set to expire **TWO MONTHS** from the mailing date of this letter.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D., can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo August 24, 2004

PRIMARY EXAMPLER

Application No. $\frac{\partial 8/958570}{\partial 958570}$

MOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

\boxtimes	1. This application clearly fails to comply with the requirements of 37 CFR 1.821
	25. Applicant's attention is directed to these regulations, published at 1114 OG 29 5, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on
oa per	copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been
SUDMI	tted as required by 37 CFR 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted.
of 37	er, the content of the computer readable form does not comply with the requirements CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw note Listing."
	5. The computer readable form that has been filed with this application has been
found Report 1.825	to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem . A substitute computer readable form must be submitted as required by 37 CFR (d).
Ш	6. The paper copy of the "Sequence Listing" is not the same as the computer
readab	ole form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:	JEQ ID NOIG does not motal sequence in specification.
A ppli	cant must provide:
Ø	An initial or substitute computer readable form (CRF) copy of the "Sequence
Listin	g"
X	An initial or substitute paper copy of the "Sequence Listing", as well as an
	amendment directing its entry into the specification
\boxtimes	A statement that the content of the paper and computer readable copies are the same
	the state of the s

For questions regarding compliance with these requirements, please contact:

and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)